blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2706113

EP2706113 - SYNTHETIC PEPTIDE CAPABLE OF INDUCING EXPRESSION OF TYPE-2 TNF RECEPTOR AND USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.01.2019
Database last updated on 10.03.2026
FormerThe patent has been granted
Status updated on  16.02.2018
FormerGrant of patent is intended
Status updated on  17.10.2017
FormerExamination is in progress
Status updated on  14.04.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
TOAGOSEI CO., LTD.
1-14-1, Nishi-Shimbashi Minato-ku
Tokyo 105-8419 / JP
[2014/11]
Inventor(s)01 / KOBAYASHI, Nahoko
c/o TOAGOSEI CO., LTD.
2 Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
02 / YOSHIDA, Tetsuhiko
c/o TOAGOSEI CO., LTD.
2 Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
03 / NIWA, Mikio
c/o TOAGOSEI CO., LTD.
2 Ookubo
Tsukuba-shi Ibaraki 300-2611 / JP
 [2014/11]
Representative(s)Elsy, David
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[N/P]
Former [2014/11]Elsy, David
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Application number, filing date12779331.317.04.2012
[2018/12]
WO2012JP60369
Priority number, dateJP2011010328202.05.2011         Original published format: JP 2011103282
[2014/11]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012150676
Date:08.11.2012
Language:JA
[2012/45]
Type: A1 Application with search report 
No.:EP2706113
Date:12.03.2014
Language:EN
[2014/11]
Type: B1 Patent specification 
No.:EP2706113
Date:21.03.2018
Language:EN
[2018/12]
Search report(s)International search report - published on:JP08.11.2012
(Supplementary) European search report - dispatched on:EP03.12.2014
ClassificationIPC:C07K14/715, A61K35/26, C07K14/47
[2017/40]
CPC:
C07K14/7151 (EP,US); C07K7/08 (US); A61P25/28 (EP);
A61P43/00 (EP); A61P5/50 (EP); A61P9/00 (EP);
A61P9/10 (EP); A61P9/14 (EP); C07K14/4705 (EP,US);
C07K7/06 (US); A61K2035/126 (US); A61K35/26 (EP,US);
A61K35/28 (US); A61K38/10 (US); C07K2319/09 (EP,US) (-)
Former IPC [2014/11]C12N5/10, A61K38/00, A61P43/00, C07K14/47, A61P5/50, A61P9/00, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/11]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SYNTHETISCHE PEPTIDE ZUR HERBEIFÜHRUNG DER EXPRESSION DES TYP-2-TNF-REZEPTORS UND VERWENDUNG DAVON[2014/11]
English:SYNTHETIC PEPTIDE CAPABLE OF INDUCING EXPRESSION OF TYPE-2 TNF RECEPTOR AND USE THEREOF[2014/11]
French:PEPTIDE SYNTHÉTIQUE CAPABLE D'INDUIRE L'EXPRESSION DU RÉCEPTEUR DE TNF DE TYPE-2 ET SON UTILISATION[2014/11]
Entry into regional phase18.11.2013Translation filed 
18.11.2013National basic fee paid 
18.11.2013Search fee paid 
18.11.2013Designation fee(s) paid 
18.11.2013Examination fee paid 
Examination procedure18.11.2013Examination requested  [2014/11]
22.06.2015Amendment by applicant (claims and/or description)
12.04.2017Despatch of a communication from the examining division (Time limit: M04)
15.08.2017Reply to a communication from the examining division
18.10.2017Communication of intention to grant the patent
02.02.2018Fee for grant paid
02.02.2018Fee for publishing/printing paid
02.02.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.04.2017
Opposition(s)02.01.2019No opposition filed within time limit [2019/09]
Fees paidRenewal fee
29.04.2014Renewal fee patent year 03
10.04.2015Renewal fee patent year 04
09.03.2016Renewal fee patent year 05
12.04.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.04.2012
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
MK21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
IE17.04.2018
LU17.04.2018
MT17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IS21.07.2018
PT23.07.2018
[2020/33]
Former [2020/31]HU17.04.2012
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
MK21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
IE17.04.2018
LU17.04.2018
MT17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2020/28]HU17.04.2012
AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
IE17.04.2018
LU17.04.2018
MT17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2020/16]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
TR21.03.2018
IE17.04.2018
LU17.04.2018
MT17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2020/08]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
IE17.04.2018
LU17.04.2018
MT17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/26]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
SM21.03.2018
IE17.04.2018
LU17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/19]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
IE17.04.2018
LU17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/12]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
LU17.04.2018
BE30.04.2018
CH30.04.2018
LI30.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/08]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
LU17.04.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/06]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/03]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2018/52]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
SM21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/50]AL21.03.2018
AT21.03.2018
CY21.03.2018
CZ21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
SK21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/49]AL21.03.2018
CY21.03.2018
EE21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/47]AL21.03.2018
CY21.03.2018
ES21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/46]AL21.03.2018
CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/45]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/40]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
RS21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/37]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NO21.06.2018
GR22.06.2018
Former [2018/35]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NO21.06.2018
Documents cited:Search[XA] WO2011013699  (TOAGOSEI CO LTD et al.) [X] 7,8 * abstract; page 22; table 1 *[A] 1-6
 [XA] EP2236514  (TOAGOSEI CO LTD et al.) [X] 7,8 * the whole document * * in particular: abstract; paragraphs [0009] - [0022]; figures 1-6; examples 1-3; claims 1-13; sequences 1-85 *[A] 1-6
 [XDA]   EDWARD EMMOTT ET AL: "Nucleolar targeting: the hub of the matter", EMBO REPORTS, vol. 10, no. 3, 1 March 2009 (2009-03-01), pages 231 - 238, XP055064640, ISSN: 1469-221X, DOI: 10.1038/embor.2009.14 [XD] 7,8 * the whole document * * in particular: abstract; page 235; table 1 *[A] 1-6

DOI:   http://dx.doi.org/10.1038/embor.2009.14
 [XDA]   M. S. SCOTT ET AL: "Characterization and prediction of protein nucleolar localization sequences", NUCLEIC ACIDS RESEARCH, vol. 38, no. 21, 1 November 2010 (2010-11-01), pages 7388 - 7399, XP055154067, ISSN: 0305-1048, DOI: 10.1093/nar/gkq653 [XD] 7,8 * the whole document * * in particular: abstract; materials and methods; results;; figures 1-5; tables 1-6 * [A] 1-6

DOI:   http://dx.doi.org/10.1093/nar/gkq653
 [A]   RAFIA S. AL-LAMKI ET AL: "Tumor Necrosis Factor Receptor Expression and Signaling in Renal Cell Carcinoma", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 177, no. 2, 1 August 2010 (2010-08-01), pages 943 - 954, XP055153980, ISSN: 0002-9440, DOI: 10.2353/ajpath.2010.091218 [A] 1-8 * the whole document * * in particular: abstract; materials and methods; results;; figures 1-8; tables 1-3 *

DOI:   http://dx.doi.org/10.2353/ajpath.2010.091218
 [A]   KOBAYASHI NAHOKO ET AL: "Nucleolar Localization Signals of LIM Kinase 2 Function as a Cell-Penetrating Peptide", PROTEIN AND PEPTIDE LETTERS, BENTHAM SCIENCE PUBLISHERS, NL, vol. 17, no. 12, 1 December 2010 (2010-12-01), pages 1480 - 1488, XP009144516, ISSN: 0929-8665 [A] 1-8 * the whole document *
International search[A]   ABU-AMER, Y. ET AL.: "Tumor Necrosis Factor Receptors Types 1 and 2 Differentially Regulate Osteoclastogenesis", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 35, 1 September 2000 (2000-09-01), pages 27307 - 27310, XP055132175

DOI:   http://dx.doi.org/10.1074/jbc.M003886200
 [A]   HIROSHI KANNO ET AL.: "Gosei Peptide no Saibonai Donyu ni yoru Kansaibo no Koritsuteki na Shinkei Bunka to sono Saisei Iryo eno Oyo", YOKOHAMA IGAKU, vol. 60, no. L, 2, 30 May 2009 (2009-05-30), pages 111 - 115, XP008171388
by applicant  THE AMERICAN JOURNAL OF PATHOLOGY, vol. 169, no. 5, 2006, pages 1886 - 1898
   NATURE REVIEWS DRUG DISCOVERY, vol. 9, 2010, pages 482 - 493
   ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 30, 2010, pages 1307 - 1314
   THE JOURNAL OF CELL BIOLOGY, vol. 178, no. 5, 2007, pages 829 - 841
   THE JOURNAL OF CLINICAL INVESTIGATION, vol. 95, 1995, pages 2409 - 2415
   NUCLEIC ACIDS RESEARCH, vol. 38, no. 21, 2010, pages 7388 - 7399
   EMBO REPORTS, vol. 10, no. 3, 2009, pages 231 - 238
   PLOS ONE, vol. 6, no. 11, January 2011 (2011-01-01), pages E27621
   SHIMIZU ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 751 - 755
   MADIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, no. 2, 2000, pages 559 - 564
   CORWIN HANSCH: "Comprehensive Medicinal Chemistry", 1990, PERGAMON PRESS
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.